Thanks for the link, Bags.
Unfortunately, this is well outside my area of competence. Just the same, here are a few (silly?) observations and questions:
1. I could only get HMAF data using the GI50 standard (estimated concentration in-vitro required for 50% tumor growth inhibition.) Data showing the TGI (estimated concentration required for total in-vitro growth inhibition) and LC50 (estimated concentration required for 50% in-vitro tumor shrinkage) standards were unavailable. I have to believe that these endpoints were also achieved in-vitro, and so, I am curious as to why the data are not available in this database.
2. The average GI50 concentration across all cell lines was on the order of 3E(-7) moles. Do you know how to translate that into the language of the dosages used in the clinical trials? Where am I headed with this? I would like to compute the fraction of the clinically established MTD that tends to yield GI50 in-vitro.
3. The data clearly show which particular tumor cell lines are the most "sensitive" to HMAF, on a relative basis (as measured by the required GI50 concentrations.) Some of the more sensitive cell lines include: RXF393 renal, DU-145 prostate, NCI-H460 and NCI-H23 non-small cell lung. Do you know anything about these cell lines? Do they represent distinct in-vivo tumor sub-types, or is the distinction primarily one of artificial differentiation (procedures used, culture medium, xenograft vs. native tumor, etc.?) If the former, do you happen to know how prevalent these cell lines are in the general cancer patient population? In other words, is there a way to determine what percentage of men diagnosed with prostate cancer, for example, will have the DU-145 tumor line, as opposed to another line?
Thanks again for all the "leg work." Much appreciated.
Regards,
RB |
